Find Neurology Drugs in Phase II/III Clinical Development in UNITED STATES

Lead Product(s): COR388

Therapeutic Area: Neurology

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2020

Details:

Data in aged dogs shows oral dosing of COR388 results in target engagement, reduction of bacterial load and beneficial effects on downstream pathology.

Lead Product(s): Rg 7916

Therapeutic Area: Neurology

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 23, 2020

Details:

The single-arm part 2 of FIREFISH study assessed the efficacy of risdiplam in 41 infants with type 1 SMA treated for 12 months. Study meets primary endpoint in patients living with type 1 SMA.

Lead Product(s): Rg 7916

Therapeutic Area: Neurology

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 23, 2020

Details:

Risdiplam demonstrated statistically significant and medically meaningful motor milestone improvement in infants with Type 1 SMA

Lead Product(s): COR388

Therapeutic Area: Neurology

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

Open-label extension study will provide COR388 to patients for an additional 48 weeks. GAIN Trial to continue as planned following pre-specified DMC safety data review.

Lead Product(s): Linoleic Acid

Therapeutic Area: Neurology

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

With this trial, Retrotope expands its pipeline of indications for RT001 which is currently being studied in a pivotal trial in Infantile Neuroaxonal Dystrophy, which is fully enrolled.